![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TF |
Gene summary for TF |
![]() |
Gene information | Species | Human | Gene symbol | TF | Gene ID | 7018 |
Gene name | transferrin | |
Gene Alias | HEL-S-71p | |
Cytomap | 3q22.1 | |
Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | A0PJA6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7018 | TF | P8T-E | Human | Esophagus | ESCC | 1.25e-10 | 4.06e-01 | 0.0889 |
7018 | TF | P10T-E | Human | Esophagus | ESCC | 1.42e-06 | -5.41e-02 | 0.116 |
7018 | TF | P16T-E | Human | Esophagus | ESCC | 1.60e-16 | 2.50e-01 | 0.1153 |
7018 | TF | P22T-E | Human | Esophagus | ESCC | 2.40e-03 | -8.78e-02 | 0.1236 |
7018 | TF | P57T-E | Human | Esophagus | ESCC | 9.24e-21 | 1.12e+00 | 0.0926 |
7018 | TF | P74T-E | Human | Esophagus | ESCC | 2.85e-03 | 1.43e-01 | 0.1479 |
7018 | TF | P76T-E | Human | Esophagus | ESCC | 5.67e-12 | 8.38e-01 | 0.1207 |
7018 | TF | P128T-E | Human | Esophagus | ESCC | 5.02e-19 | 1.31e+00 | 0.1241 |
7018 | TF | NAFLD1 | Human | Liver | NAFLD | 1.33e-14 | 1.52e+00 | -0.04 |
7018 | TF | S43 | Human | Liver | Cirrhotic | 1.96e-06 | 4.81e-01 | -0.0187 |
7018 | TF | HCC1_Meng | Human | Liver | HCC | 7.28e-77 | 1.16e+00 | 0.0246 |
7018 | TF | HCC2_Meng | Human | Liver | HCC | 6.25e-19 | -6.79e-01 | 0.0107 |
7018 | TF | cirrhotic1 | Human | Liver | Cirrhotic | 3.69e-15 | -1.70e-01 | 0.0202 |
7018 | TF | cirrhotic2 | Human | Liver | Cirrhotic | 1.67e-15 | -1.87e-01 | 0.0201 |
7018 | TF | cirrhotic3 | Human | Liver | Cirrhotic | 2.61e-02 | -4.09e-01 | 0.0215 |
7018 | TF | HCC1 | Human | Liver | HCC | 7.61e-40 | 8.09e+00 | 0.5336 |
7018 | TF | HCC2 | Human | Liver | HCC | 6.48e-53 | 8.08e+00 | 0.5341 |
7018 | TF | HCC5 | Human | Liver | HCC | 3.83e-07 | 4.78e+00 | 0.4932 |
7018 | TF | Pt13.a | Human | Liver | HCC | 1.44e-27 | 2.57e-01 | 0.021 |
7018 | TF | Pt13.b | Human | Liver | HCC | 8.21e-34 | 3.51e-02 | 0.0251 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586010 | Prostate | BPH | positive regulation of protein kinase activity | 104/3107 | 386/18723 | 1.52e-07 | 3.51e-06 | 104 |
GO:00068887 | Prostate | BPH | endoplasmic reticulum to Golgi vesicle-mediated transport | 46/3107 | 130/18723 | 1.53e-07 | 3.53e-06 | 46 |
GO:00165706 | Prostate | BPH | histone modification | 120/3107 | 463/18723 | 1.73e-07 | 3.89e-06 | 120 |
GO:00443195 | Prostate | BPH | wound healing, spreading of cells | 19/3107 | 34/18723 | 2.09e-07 | 4.59e-06 | 19 |
GO:00905055 | Prostate | BPH | epiboly involved in wound healing | 19/3107 | 34/18723 | 2.09e-07 | 4.59e-06 | 19 |
GO:000926710 | Prostate | BPH | cellular response to starvation | 52/3107 | 156/18723 | 2.24e-07 | 4.89e-06 | 52 |
GO:007099718 | Prostate | BPH | neuron death | 98/3107 | 361/18723 | 2.35e-07 | 5.12e-06 | 98 |
GO:004343417 | Prostate | BPH | response to peptide hormone | 109/3107 | 414/18723 | 2.73e-07 | 5.91e-06 | 109 |
GO:000961510 | Prostate | BPH | response to virus | 99/3107 | 367/18723 | 2.82e-07 | 6.07e-06 | 99 |
GO:190121618 | Prostate | BPH | positive regulation of neuron death | 37/3107 | 97/18723 | 2.88e-07 | 6.16e-06 | 37 |
GO:00719009 | Prostate | BPH | regulation of protein serine/threonine kinase activity | 97/3107 | 359/18723 | 3.42e-07 | 7.23e-06 | 97 |
GO:003166718 | Prostate | BPH | response to nutrient levels | 121/3107 | 474/18723 | 3.68e-07 | 7.70e-06 | 121 |
GO:003465515 | Prostate | BPH | nucleobase-containing compound catabolic process | 107/3107 | 407/18723 | 3.79e-07 | 7.89e-06 | 107 |
GO:00905045 | Prostate | BPH | epiboly | 19/3107 | 35/18723 | 3.86e-07 | 8.02e-06 | 19 |
GO:00015039 | Prostate | BPH | ossification | 107/3107 | 408/18723 | 4.31e-07 | 8.83e-06 | 107 |
GO:005079218 | Prostate | BPH | regulation of viral process | 53/3107 | 164/18723 | 5.22e-07 | 1.04e-05 | 53 |
GO:19028957 | Prostate | BPH | positive regulation of pri-miRNA transcription by RNA polymerase II | 21/3107 | 42/18723 | 5.88e-07 | 1.15e-05 | 21 |
GO:00072499 | Prostate | BPH | I-kappaB kinase/NF-kappaB signaling | 79/3107 | 281/18723 | 7.61e-07 | 1.43e-05 | 79 |
GO:004339316 | Prostate | BPH | regulation of protein binding | 60/3107 | 196/18723 | 7.72e-07 | 1.45e-05 | 60 |
GO:005110017 | Prostate | BPH | negative regulation of binding | 52/3107 | 162/18723 | 8.41e-07 | 1.56e-05 | 52 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0406629 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa04066113 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
hsa0435014 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0421621 | Liver | Cirrhotic | Ferroptosis | 23/2530 | 41/8465 | 4.09e-04 | 2.57e-03 | 1.58e-03 | 23 |
hsa0406612 | Liver | Cirrhotic | HIF-1 signaling pathway | 46/2530 | 109/8465 | 4.00e-03 | 1.59e-02 | 9.78e-03 | 46 |
hsa0421631 | Liver | Cirrhotic | Ferroptosis | 23/2530 | 41/8465 | 4.09e-04 | 2.57e-03 | 1.58e-03 | 23 |
hsa0406613 | Liver | Cirrhotic | HIF-1 signaling pathway | 46/2530 | 109/8465 | 4.00e-03 | 1.59e-02 | 9.78e-03 | 46 |
hsa0421641 | Liver | HCC | Ferroptosis | 33/4020 | 41/8465 | 1.42e-05 | 9.88e-05 | 5.50e-05 | 33 |
hsa0406622 | Liver | HCC | HIF-1 signaling pathway | 70/4020 | 109/8465 | 2.96e-04 | 1.36e-03 | 7.57e-04 | 70 |
hsa0421651 | Liver | HCC | Ferroptosis | 33/4020 | 41/8465 | 1.42e-05 | 9.88e-05 | 5.50e-05 | 33 |
hsa0406632 | Liver | HCC | HIF-1 signaling pathway | 70/4020 | 109/8465 | 2.96e-04 | 1.36e-03 | 7.57e-04 | 70 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TF | SNV | Missense_Mutation | c.1906N>T | p.Gly636Cys | p.G636C | P02787 | protein_coding | deleterious(0.01) | possibly_damaging(0.767) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
TF | SNV | Missense_Mutation | novel | c.693N>T | p.Glu231Asp | p.E231D | P02787 | protein_coding | tolerated(0.09) | benign(0.138) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TF | SNV | Missense_Mutation | c.1009N>C | p.Glu337Gln | p.E337Q | P02787 | protein_coding | tolerated(0.24) | benign(0.03) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
TF | SNV | Missense_Mutation | c.1565N>C | p.Leu522Pro | p.L522P | P02787 | protein_coding | tolerated(0.35) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
TF | SNV | Missense_Mutation | novel | c.1816N>C | p.Val606Leu | p.V606L | P02787 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TF | SNV | Missense_Mutation | novel | c.1073G>T | p.Cys358Phe | p.C358F | P02787 | protein_coding | deleterious(0.05) | benign(0.097) | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TF | SNV | Missense_Mutation | novel | c.161N>T | p.Pro54Leu | p.P54L | P02787 | protein_coding | tolerated(0.06) | possibly_damaging(0.843) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
TF | SNV | Missense_Mutation | c.1907N>T | p.Gly636Val | p.G636V | P02787 | protein_coding | tolerated(0.05) | benign(0.375) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TF | SNV | Missense_Mutation | c.493C>G | p.Leu165Val | p.L165V | P02787 | protein_coding | tolerated(0.45) | benign(0.035) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TF | insertion | Frame_Shift_Ins | novel | c.2011_2012insCCTCTGGGGGAACAACCACTCA | p.Gly671AlafsTer17 | p.G671Afs*17 | P02787 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | adalimumab | ADALIMUMAB | 27115882 | |
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | Ademetionine | ADEMETIONINE | ||
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | CALAA-01 | |||
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | PF-06763809 | |||
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | EP-2167 |
Page: 1 |